^
Association details:
| Biomarker: | RAS wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Excerpt:
...If the participant has RAS wild type colorectal cancer, he or she also must have received prior treatment with an epidermal growth factor receptor monoclonal antibody...
Trial ID:
Source:
Title:
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
Published date:
09/12/2023
Excerpt:
Six-month PFS rate was 58.2% (90% CI 49.3% to 66.2%) with a median PFS of 7.0 months (95% CI 5.7-7.6 months). Median OS was 23.6 months (95% CI 16.5-26.3 months). The ORR and ETS rate were 10.7% and 16.9%, respectively, in 83 patients with measurable lesions....Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC.
Secondary therapy:
FOLFIRI
DOI:
https://doi.org/10.1016/j.esmoop.2023.101636
Source:
Title:
Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16
Published date:
06/29/2022
Excerpt:
The JACCRO CC-16 was a single arm, phase 2 trial to evaluate the efficacy and safety of RAM (8 mg/kg) plus FOLFIRI (irinotecan 150 mg/m2, bolus 5-FU 400 mg/m2, infusional 5-FU 2400 mg/m2) in mCRC patients with RAS wild-type tumors...The PFS was significantly longer in the doublet group (median PFS, 7.4 months, 95% CI 5.7 to 9.0) compared to the triplet group (median PFS, 6.4 months, 95% CI 3.8 to 7.35) (p ¼ 0.036, log-rank test)....This study demonstrated a favorable efficacy of FOLFIRI plus RAM treatment in RAS wild-type mCRC patients.
Secondary therapy:
FOLFIRI
DOI:
10.1016/j.annonc.2022.04.197
Source:
Title:
A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16. Add to Collection
Published date:
01/18/2022
Excerpt:
We therefore investigated the efficacy and safety of RAM plus FOLFIRI as second-line treatment in patients with RAS wild-type mCRC... Primary endpoint was met; at data cut-off, with 76 events, 6-month PFS rate was 58.2% (95% CI; 47.4-67.6). The median PFS was 7.0 months. The ORR, disease control rate, and ETS were 10.7%, 86.9%, and 16.9%, respectively....This is the first prospective study to demonstrate that RAM plus FOLFIRI as second-line treatment has favorable PFS rate and tolerability after anti-EGFR antibody containing chemotherapy in RAS wild-type mCRC patients.
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2022.40.4_suppl.112
